STRO
SUTRO BIOPHARMA, INC.
NASDAQ · Healthcare · Biotechnology · US
$9.19
+0.55%Year over year
Reported trailing growth
- Revenue
- -56.3%
- EBITDA
- +5.9%
- EBIT
- +30.9%
- EPS
- +30.9%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -16.8%
- EBITDA
- +45.7%
- EPS
- +59.3%
Three-year CAGR
- Revenue
- +14.8%
- EBITDA
- +19.3%
- EBIT
- +56.0%
- Net income
- +16.0%
- EPS
- +24.0%
- Free cash flow
- +8.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026